Premium
Swietenine extracted from Swietenia relieves myocardial hypertrophy induced by isoprenaline in mice
Author(s) -
Ding Jingjing,
Liu Shoubai,
Qian Weichun,
Wang Jiacheng,
Chu Chunyan,
Wang Juejin,
Li Kai,
Yu Youjia,
Xu Guanhong,
Mao Zhengsheng,
Xiao Pingxi,
Yu Yanfang,
Chen Feng
Publication year - 2020
Publication title -
environmental toxicology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.813
H-Index - 77
eISSN - 1522-7278
pISSN - 1520-4081
DOI - 10.1002/tox.22999
Subject(s) - isoprenaline , muscle hypertrophy , myocardial hypertrophy , western blot , medicine , in vivo , pathological , protein kinase b , cardiology , swietenia macrophylla , endocrinology , phosphorylation , biology , botany , microbiology and biotechnology , gene , biochemistry , stimulation
As a traditional plant medicine in tropical areas, Swietenia macrophylla seeds are usually applied for some chronic diseases, including hypertension, diabetes, and so on. Few studies have been carried out to identify the effective elements in seed extract and their indications. In this study, we first investigated the functions of the swietenine, an extract from S. macrophylla seeds, using a model of myocardial hypertrophy induced by isoprenaline (ISO). At cellular level, H9c2 cell hypertrophy was also established through the treatment with ISO. The cardiac pathological remodeling was evaluated by echocardiography and histological analysis. Western blot and RT‐qPCR were used to detect the expression of possible hypertrophy‐promoting genes. Here, our results indicated that swietenine remarkably attenuated ISO‐induced myocardial hypertrophy in vivo and in vitro. Moreover, Akt phosphorylation, ANP and BNP mRNA expression were efficiently decreased . Based on these findings, we concluded that swietenine might be a promising anti‐hypertrophic agent against cardiac hypertrophy.